Lucida Medical

Lucida Medical is heading to BSUR in Birmingham! Join Dr Antony Rix on 21 May, 13:15–13:45 for insights on AI in prostate cancer pathways. Visit us at Booth 1 or book a meeting: @lucidamedical.com/?ismsaljsauthenabled" target="_blank" rel="nofollow noopener">outlook.office.com/book/BSUR2026@…

We’re pleased to announce the nine high-potential innovators selected for the Grow #DigitalHealth Midlands 2026 cohort delivered in collaboration by @Healthinn_em & HIWM. Meet the innovators: healthinnovationwestmidlands.org/grow-digital-h… #HealthInnovation #NHS #MedTech #WestMidlands #EastMidlands

BSUR are super excited about the upcoming conference in Birmingham Thanks to all the great sponsors below who enable us to put on such a great event @LucidaMedical @CanonUKandIE @HLHImagingGroup @ArgonMedical @QuibimBiomarker @Bayer @SiemensHealth @QuibimBiomarker @DeepHealthEU

Following last week’s software release, we’re highlighting one of the updates designed to make clinicians’ work easier: segmentation editing. Pi™ lets clinicians adjust, remove or draw lesion segmentations before sending to PACS, giving more control and a faster workflow.

Lucida Medical is now a member of AXREM, the UK’s leading association for imaging, radiotherapy, healthcare IT and care equipment. We’re excited to collaborate with fellow members, advance patient outcomes, and contribute to the AXREM AI Special Focus Group!

Learn more about the research paper: Sushentsev N, Arya Z, Budd J et al, AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study, European Radiology 2026: doi.org/10.1007/s00330…

A sharper way to assess prostate cancer risk is here. Pi™ now delivers an integrated risk score combining MRI AI, PSA and PIRADS®. Published evidence shows ~20% fewer unnecessary biopsies with maintained csPCa detection. Full announcement: lucidamedical.com/new-software-l…

Read about PAIR-1: link.springer.com/article/10.100…

Our PAIR‑1 study was ranked among the Top 5 most downloaded articles in European Radiology for 2025! At ECR, Prof. Anwar Padhani (@ProfPadhani ) received the official acknowledgment on behalf of all collaborators for this achievement. Thank you for your support!

Lucida Medical has secured £8.7m in funding led by IW Capital, with participation from XTX Ventures and Macmillan Cancer Support. This investment will advance our patented AI for prostate cancer diagnosis and support our international expansion. lucidamedical.com/lucida-medical…

We will be at ECR 2026, 4-8 March 2026! 📍 Booth location: AI‑32, AI Exhibition Area 🔗 Book a meeting with our team: @lucidamedical.com/?ismsaljsauthenabled" target="_blank" rel="nofollow noopener">outlook.office.com/book/ECR2026@l… We look forward to meeting colleagues and partners in Vienna to discuss how evidence‑based AI can strengthen prostate cancer care.

AI decision support in prostate MRI can boost accuracy, cut variability, and sharpen decisions on PI‑RADS 3 cases. The challenge is using AI insight without slipping into automation bias. How do you see this shaping everyday reporting?

We welcome Dr. Luca Russo as Clinical Lead on our Medical Advisory Board! He is a Radiologist at Gemelli Hospital, a Clinical Research Fellow at The Royal Marsden in London, and holds a PhD in Oncological Sciences. His expertise will further strengthen our clinical impact!

2025 has been a year of progress at Lucida Medical: new clinical validations, product upgrades, partnerships, and impactful congresses. With trust, passion and vision, we look forward to 2026, driving innovation and reaching new milestones in the prostate care pathway.

When AI acts as a second reader, MDTs gain safety checks but face new risks: bias, trust gaps, overdiagnosis. How can teams strike balance between AI’s sensitivity & human judgment in biopsy decisions? Full paper: link.springer.com/article/10.100…

For this year’s Christmas party, we gathered at King’s College in Cambridge 🎄 The setting was iconic, but what mattered most was the chance to pause and see each other. We close the year proud of the progress made, and we are excited for the milestones ahead!

Improving early detection and tackling inequalities in prostate cancer screening is vital, and we’re proud to support our partners at Prostate Cancer Research in raising awareness of this important issue. Find out more and add your voice here: act.prostate-cancer-research.org.uk/a/say-yes-to-s…

We are thrilled to complete the first prostate fusion biopsy procedure at our pilot site Hampshire Hospitals NHS Foundation Trust! The procedure was performed through @SectraNews Amplifier Service, and combined with the @KoelisBx Trinity®. Read more: lucidamedical.com/press-release-…

#RSNA2025 is almost here and we’re excited to share new research on how AI decision support could enable significant biopsy reduction. This multicentre study integrates PI-RADS, PSA density, and AI risk scores to sharpen biopsy selectivity. Join us on Dec 2 to learn more!

Lucida Medical’s first newsletter arrives this week! Be among the first to receive updates on milestones, research, and product developments. 📩 Sign up before launch: lucidamedical.com/newsletter-sub…